Abstract: A canola protein isolate consisting predominantly of 2S canola protein and having improved solubility properties, has an increased proportion of 2S canola protein and a decreased proportion of 7S canola protein. The canola protein isolate is formed by heat treatment of aqueous supernatant from canola protein micelle formation and precipitation, to effect precipitation of 7S protein which is sedimented and removed.
Type:
Grant
Filed:
January 20, 2005
Date of Patent:
November 3, 2009
Assignee:
Burcon Nutrascience (MB) Corp.
Inventors:
Martin Schweizer, Brent E. Green, Kevin I. Segall, Randy Willardsen
Abstract: The use of extracts from Pelargonium species or plant parts thereof, particularly from P. sidoides and P. reniforme for the prophylaxis or treatment of disease-related behavioral changes, the chronic or post-viral asthenia syndrome and/or stress-induced chronic pathological conditions as well as pharmaceutical preparations containing these extracts are described.
Type:
Grant
Filed:
October 26, 2004
Date of Patent:
November 3, 2009
Assignee:
ISO Arzneiminel GmbH & Co. KG
Inventors:
Shyam Sunder Chatterjee, Egon Koch, Michael Nöldner
Abstract: A Phytoceutical composition for the prevention and treatment of hyperlipidemia—cholesterol and triglyceride disorder—is provided. A specific combination of extracts of plants and nutraceuticals is taught, as well as principles for varying the formulations based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants and nutraceuticals from each group. Such combinations have synergistic effects, with minimal side effects.
Abstract: Onions (Allium Cepa and its close relatives, as opposed to Allium Sativum) contain potent coagulation modulators, as well as platelet inhibitors. Clinical, in vivo and in vitro testing confirms that the efficacy of commonly consumed quantities of onions in terms of the efficacy of its impact on coagulation and platelet function rivals and in many respects exceeds the potency of any other modalities available today. Additionally, onion compounds have unique effects as described later in this application.
Abstract: Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1? mediated adhesion of polymorphonuclear leukocytes. The hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts. The secondary anti-inflammatory agents may or may not function by antagonizing LTB4-mediated chemotaxis and IL-1? mediated adhesion. The extract may be incorporated into a cosmetically acceptable vehicle. The present invention includes methods of treating skin inflammation by applying to inflamed skin, anti-inflammatory effective amounts of Hypsizygus ulmarius extract in a defined treatment regimen.
Abstract: A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunoreceptive to the NEPA such as HBsAg by administering the plant material containing the NEPA in conjunction with a suitable adjuvant. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing the NEPA, e.g. hepatitis B surface antigen (HBsAg). The NEPA, e.g. HBsAg in the plant results from expression by the plant of the NEPA due to genetic alteration.
Type:
Grant
Filed:
December 16, 1999
Date of Patent:
August 11, 2009
Assignees:
Health Research, Inc., Boyce Thompson Institute for Plant Research, Inc.
Inventors:
Yasmin Thanavala, Charles Joel Arntzen, Hugh S. Mason
Abstract: Methods for extraction of carotenoids from carotenoid-containing plant material using an extraction solvent comprising ethyl lactate. The invention is also directed to products obtained thereby. In the method, a sample of dry, particulate carotenoid-containing plant material is contacted with the ethyl lactate extraction solvent to extract the carotenoids. The method also includes the use of an ethyl lactate-ethanol blend as the extraction solvent. After extraction, the solvent containing the extracted carotenoids is separated from the extracted plant solids and treated to separate the dissolved carotenoids from the extraction solvent and obtain a carotenoid-containing concentrate. The concentrated carotenoid product may be used directly or may be subjected to further treatment. After removal of the dissolved carotenoids, the extraction solvent can be recycled for further use.
Type:
Grant
Filed:
December 27, 2005
Date of Patent:
August 11, 2009
Assignees:
The United States of America as represented by the Secretary of Agriculture, United Technologies
Inventors:
Betty K. Ishida, Mary H. Chapman, Sarabjit Singh Randhava, Sikander Singh Randhava
Abstract: A composition and method for direct application to mucosal membranes, which combines naturally occurring phytoestrogens, such as plant extracts and soy isoflavones, with other active and inactive ingredients in a convenient medium, such as an aqueous cream, aqueous spray or suppository. The composition may be used for the treatment of dry or inadequately hydrated mucosal surfaces, and related complications, such as those affecting the nasal passages or vagina.
Abstract: A cosmetic composition comprising, as active agent, an extract of biomass of the alga Neochloris oleoabundans, the active agent being incorporated in a cosmetically acceptable vehicle compatible with topical application. This extract is advantageously an alcoholic or aqueous-alcoholic extract, called the first extract obtained by treating the biomass with a first alcoholic or aqueous-alcoholic solvent, and/or at least one fraction of the first extract, obtained by fractionating the first extract.
Abstract: An ethyl acetate extract of Opuntia ficus-indica and compounds isolated therefrom for preventing and treating brain diseases such as Alzheimer's disease, stroke and Parkinson's disease, cell and tissue damage caused by ischemia, or cardiovascular system disease such as myocardial infarction.
Type:
Grant
Filed:
October 29, 2002
Date of Patent:
July 21, 2009
Assignee:
Korea Institute of Science and Technology
Inventors:
Yong Sup Lee, Hokoon Park, Changbae Jin, Hyoung Ja Kim, Jungsook Cho, Mijeong Park, Yunaaon Song
Abstract: Methods for treating constipation-predominant irritable bowel syndrome comprise administering to a patient in need thereof a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat constipation-predominant irritable bowel syndrome (c-IBS). Treatment of c-IBS includes the treatment of the constipation component of c-IBS as well as the pain and abdominal discomfort associated with c-IBS. In one embodiment, the polymeric proanthocyanidin compound is crofelemer. In addition, methods for treating alternating constipation-predominant/diarrhea-predominant irritable bowel syndrome are an alternative embodiment of the invention.
Abstract: Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluted at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.
Type:
Grant
Filed:
October 23, 2003
Date of Patent:
June 9, 2009
Assignee:
Talecris Biotherapeutics, Inc.
Inventors:
Rita T. Bradley, Scott A. Cook, Christopher A. Dadd, Jonathan D. Kent, Marina N. Korneyeva, Valery V. Novokhatny, James F. Rebbeor, Christopher J. Stenland, Jonathan S. Strauss, Jarrett C. Terry, Jeffrey A. Yuziuk
Abstract: Methods and composition using plants from the Irvingiaceae family to reduce or prevent one or more symptoms of Syndrome X in a mammal and provide numerous other health related benefits. Methods and compositions using the Irvinga gabonensis plant to reduce lipid levels, BMI and body weight, blood pressure, triglyceride levels, total amount of stored in the body, cholesterol levels, salivary and pancreatic alpha-amylase activity and pancreatic lipase activity, LDL cholesterol, to increase HDL cholesterol, to control blood glucose and to prevent or reduce the effects of insulin resistance, diabetes, and heart disease.
Abstract: A method for obtaining an immune response to hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the HBsAg. It has now been discovered that the animal may be made immunoreceptive to HBsAg either by administering the plant material containing HBsAg in conjunction with a suitable adjuvant or by prior primary immunization. When the animal is made immunoreceptive by a prior, e.g. primary, immunization, an immune response to HBsAg may be boosted in the animal by feeding the animal the plant material containing the HBsAg. For example, an animal, e.g. a human, that previously had a positive response to primary immunization against hepatitis B, can have a booster response to HBsAg by feeding the animal the antigen in a plant material. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing hepatitis B surface antigen (HBsAg).
Type:
Grant
Filed:
October 19, 1999
Date of Patent:
May 5, 2009
Assignees:
Health Research, Inc., Boyce Thompson Institute for Plant Research, Inc
Inventors:
Yasmin Thanavala, Charles Joel Arntzen, Hugh S. Mason
Abstract: A method for treating/relief of women's menstruation pain. The pain is reduced or relieved by externally administering an effective amount of an essential oil obtained from anthopogon.
Abstract: A method of reducing gastric acid secretion in animals including humans comprising administering an extract of a plant of the genus Hoodia or Trichocaulon to animals, generally mammals.
Type:
Grant
Filed:
August 19, 2004
Date of Patent:
March 10, 2009
Assignee:
Conopco, Inc.
Inventors:
John Hakkinen, Roelof Marthinus Horak, Vinesh Maharaj
Abstract: Weight-controlling or modulating compositions, systems, and methods are disclosed and described. Such compositions may include a thermogenic ingredient, a cortisol modulating ingredient, and a carbohydrate craving controlling ingredient. Furthermore, such compositions may be used in connection with exercise and dietary modifications or restrictions.
Abstract: A pharmaceutical composition which can be used to prevent and treat bone fracture and osteoporosis. The composition is composed of Semen lactucae sativae 0.1-1, Lignum aquilariae resinatum 2-20, Fructus oryzae 1-5, Resina boswelliae carterii 0.1-1, Rhizoma atractylodis macrocephalae 0.1-1 and Semen cuscutae 0.1-1. The whole or the specific parts of the plants can be used to prepare the inventive pharmaceutical composition; preferred plants are Aquilariae lignum containing resin and Boswellia carterii containing resin. This pharmaceutical composition can be formulated into lozenge, tablet, film coated tablets, capsule, soft capsule, granule, powder, pill, solution, emulsion, injection solution, injection, ointment, cream, spray or inhalant.
Abstract: A method for prevention or therapy of pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria by administration of two kinds of crude drugs—seeds of Cucurbita moschata and flowers of Carthamus tinctorius—and at least one crude drug selected from Plantago asiatica, Lonicera japonica, Glycyrrhiza uralensis, Coix lachrymal-jobi var. ma-yuen, Zingiber officinale, Curcuma longa, Curcuma zedoaria and Artemisia argyi to a patient; and a health food for prevention, or improvement, or reduction of these symptoms containing the above substances.